PMID: 16507220Mar 2, 2006Paper

Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics

Current Oncology Reports
Snehal G ThakkarJorge A Garcia

Abstract

The endothelins (ETs), which include ET-1, ET-2, ET-3, and their receptors ET-A and ET-B, play a major role in tumor growth, proliferation, apoptosis, angiogenesis, and bone metastasis. Atrasentan is a novel and selective inhibitor of ET-1 and ET-A. In vitro and in vivo data show that this oral agent is capable of inhibiting tumor cells in vitro. More recently, this agent was studied in several phase I trials with refractory carcinoma patients. Subsequently, phase II and III clinical trials evaluating atrasentan in patients with hormone-refractory prostate carcinoma have suggested that targeting this pathway may be a new therapeutic strategy in the treatment of solid malignancies, specifically, prostate cancer.

References

Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A InoueT Masaki
Aug 10, 1995·The New England Journal of Medicine·E R Levin
May 30, 1994·Biochemical and Biophysical Research Communications·J J YohnM R Zamora
Mar 1, 1993·Peptides·B BattistiniP Sirois
Feb 27, 1996·Biochemical and Biophysical Research Communications·K KikuchiK Tamaki
Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S MoraitisW R Miller
Mar 5, 1999·Clinical and Experimental Pharmacology & Physiology·R G Goldie
Jun 26, 1999·The Journal of Investigative Dermatology·J EberleC E Orfanos
Oct 12, 1999·Endocrine-related Cancer·B F BoyceT A Guise
Mar 30, 2000·International Journal of Cancer. Journal International Du Cancer·L P EberlL Juillerat-Jeanneret
Apr 4, 2000·American Journal of Respiratory Cell and Molecular Biology·S I AhmedP J Woll
Apr 26, 2000·BJU International·J B Nelson, M A Carducci
Sep 8, 2000·Journal of Cardiovascular Pharmacology·T Masaki
Oct 29, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·A VenutiA Bagnato
Nov 14, 2000·The American Journal of Pathology·D SalaniA Bagnato
Nov 15, 2000·Journal of Cardiovascular Pharmacology·E L Bek, M A McMillen
Nov 15, 2000·Journal of Cardiovascular Pharmacology·L P EberlL Juillerat-Jeanneret
Dec 7, 2000·The American Journal of Pathology·G EgidyF Pinet
Feb 15, 2001·The Journal of Urology·K GohjiM Nakajima
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A CarducciRobert J Padley
Aug 24, 2002·Clinical Science·Laura RosanòAnna Bagnato
Feb 4, 2003·Nature Reviews. Cancer·Joel NelsonPerry Nisen
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A CarducciJoel B Nelson
Sep 10, 2003·Proceedings of the National Academy of Sciences of the United States of America·Gregory R Mundy
Jul 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher W RyanMark J Ratain
Apr 15, 2008·Trends in Endocrinology and Metabolism : TEM·A Bagnato, K J Catt

❮ Previous
Next ❯

Citations

Nov 17, 2007·Clinical & Experimental Metastasis·Philippe Clezardin, Anna Teti
Dec 11, 2007·Nucleosides, Nucleotides & Nucleic Acids·Gabriela IvanovaChristian Leumann
Jul 10, 2010·OncoTargets and Therapy·Prakash Vishnu, Winston W Tan
Mar 4, 2008·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Pierre Sonveaux
Jul 24, 2007·The Journal of Urology·Deborah A BradleyPhilip Kantoff
Jun 20, 2008·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·B-J ZhaoX Ma
Mar 2, 2011·BJU International·Roger S Kirby, John M Fitzpatrick
Oct 8, 2014·Archivum Immunologiae Et Therapiae Experimentalis·Agata KowalczykAnna Goraca
Sep 25, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Hielke J MeulenbeldRonald de Wit
Feb 28, 2008·The Cancer Journal·Deborah A Bradley, Maha Hussain
May 13, 2017·Current Osteoporosis Reports·Daniel P MilgromTeresa A Zimmers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis